Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Hasbro, Inc. (HAS) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance

Hasbro, Inc.Trade
Vertex Pharmaceuticals IncorporatedTrade

Price performance (Past 24H)

Key statistics

Hasbro, Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? Hasbro, Inc. trades at $97.28 (market cap $13.33B), while Vertex Pharmaceuticals Incorporated trades at $526.33 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 10× Hasbro, Inc.'s market cap, and Hasbro, Inc. pays a 2.96% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.

HASVRTX
Market Cap
$13.33B$132.79B
Sector
Consumer CyclicalHealth
52-Week High
$105.88$529.59
52-Week Low
$70.95$374.46
Enterprise Value
$15.52B$126.92B
Dividend Yield
2.96%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Hasbro, Inc.

Hasbro (HAS) trades at $93.52, up 2.0% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust revenue growth driven by Magic: The Gathering and digital gaming, though net income turned negative in 2025. Analyst consensus is a Buy with a $104.90 price target, supported by institutional accumulation and positive media coverage on franchise strength.

Outlook remains positive with 2026 revenue projected at $5.0B and net income of $794M, but risks include high debt levels, margin pressures from tariffs, and cybersecurity concerns. The stock offers a 2.93% dividend yield, with upside potential if growth sustains, yet volatility may persist amid cost headwinds.

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.

Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.

Returns comparison

Trailing returns across standard periods

About Hasbro, Inc.

Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.

Read more on HAS

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Read more on VRTX